Foster & Motley Inc. Has $3.44 Million Stock Position in Pfizer Inc. $PFE

Key Points

• Foster & Motley Inc. increased its stake in Pfizer Inc. by 17.6%, now holding 141,917 shares worth approximately $3.44 million.
• Pfizer reported $0.78 earnings per share in its latest quarter, surpassing analyst expectations and showcasing a revenue increase of 10.3% year-over-year.
• The company declared a quarterly dividend of $0.43 per share, representing an annualized yield of 7.0%, with the ex-dividend date set for November 7th.

Foster & Motley Inc. boosted its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 17.6% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 141,917 shares of the biopharmaceutical company's stock after buying an additional 21,246 shares during the period. Foster & Motley Inc.'s holdings in Pfizer were worth $3,440,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. GKV Capital Management Co. Inc. acquired a new position in Pfizer in the 1st quarter valued at about $27,000. Bayforest Capital Ltd acquired a new position in Pfizer in the 1st quarter valued at about $28,000. North Capital Inc. acquired a new position in Pfizer in the 1st quarter valued at about $28,000. Harbor Asset Planning Inc. acquired a new position in shares of Pfizer during the 2nd quarter worth approximately $29,000. Finally, WPG Advisers LLC acquired a new position in shares of Pfizer during the 1st quarter worth approximately $35,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Performance

NYSE PFE opened at $24.52 on Friday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $139.38 billion, a price-to-earnings ratio of 13.04, a P/E/G ratio of 0.81 and a beta of 0.55. The firm's 50 day simple moving average is $24.89 and its 200 day simple moving average is $24.11. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $29.36.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same quarter last year, the business posted $0.60 earnings per share. The company's quarterly revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be given a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. Pfizer's dividend payout ratio (DPR) is currently 91.49%.

Analyst Ratings Changes

A number of brokerages have issued reports on PFE. Bank of America increased their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a research report on Friday, October 3rd. Citigroup increased their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Weiss Ratings restated a "hold (c-)" rating on shares of Pfizer in a research report on Wednesday, October 8th. Wall Street Zen lowered shares of Pfizer from a "buy" rating to a "hold" rating in a research report on Sunday, September 28th. Finally, Morgan Stanley decreased their target price on shares of Pfizer from $33.00 to $32.00 and set an "equal weight" rating on the stock in a research report on Friday, October 10th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Pfizer presently has an average rating of "Hold" and a consensus target price of $28.13.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.